je.st
news
Tag: lung
UPDATE 2-Bristol's Opdivo proves effective against second type of lung cancer
2015-04-18 15:28:57| Biotech - Topix.net
A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. The U.S. drugmaker on Friday said the study, called Checkmate-057, was stopped early after an independent data monitoring committee concluded that Opdivo provided a survival advantage over docetaxel, a standard chemotherapy, among patients with previously treated non-squamous non-small cell lung cancer .
Tags: type
update
effective
cancer
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA (pembrolizumab) in Lung Cancer and Melanoma
2015-03-31 14:00:00| Merck.com - Product News
Dateline City: WALTHAM, Mass. & KENILWORTH, N.J. WALTHAM, Mass. & KENILWORTH, N.J.--(BUSINESS WIRE)--Syndax Pharmaceuticals, Inc., and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndaxs entinostat, an investigational epigenetic therapy, with Mercks KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orSyndax Corporate:Bob Goodenow, 781-419-1418Chief Business Officerbgoodenow@syndax.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
combination
cancer
evaluating
New Data Investigating Mercks KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
2015-03-18 21:19:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Data to be Presented Across Multiple Tumor Types for KEYTRUDA and MK-8628 (OTX015), an Investigational BET-Bromodomain Inhibitor KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in both advanced non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma will be presented as part of the Clinical Trials Plenary Session on Sunday, April 19 at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, April 18 22. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
presented
cell
Well: Childrens Lung Health Improves as Air Pollution Is Reduced, Study Says
2015-03-04 23:38:00| Climate Ark Climate Change & Global Warming Newsfeed
New York Times: For the first time, researchers have shown that reducing air pollution leads to improved respiratory function in children ages 11 to 15, a critical period of lung development. Scientists have long known that air pollution is linked to smaller lung capacity and compromised breathing in children. But it had not been clear whether, and to what extent, a reduction in air pollution over the years might prevent these problems. Environmentalists have maintained that federal emission standards are not...
FDA approves Bristol-Myers drug for lung cancer
2015-03-04 21:48:13| Biotech - Topix.net
The Food and Drug Administration on Wednesday expanded approval of an innovative Bristol-Myers Squibb drug to treat the most common form of lung cancer. Regulators cleared Opdivo for patients with advanced squamous non-small cell lung cancer, which accounts for seven out of eight lung cancer patients.
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »